J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 8, Number 12, December 2016, pages 854-858

Effects of Helicobacter pylori Eradication on the Platelet Count in Hepatitis C Virus-Infected Patients

**Table 1.** Characteristics of the *H. pylori*-Positive Patients (N = 30)
Age (years)	68.8 ± 5.0
Gender (male/female)	16/14
AST (IU/L)	60.5 ± 33.1
ALT (IU/L)	57.8 ± 42.5
γ-GTP (IU/L)	47.0 ± 31.3
ALP (IU/L)	281.5 ± 87.6
Total bilirubin (mg/dL)	0.9 ± 0.3
Albumin (g/dL)	3.8 ± 0.5
Hemoglobin (g/dL)	12.3 ± 1.8
Platelets (× 10³/μL)	98.2 ± 40.9
Prothrombin time (%)	80.9 ± 12.0
HCV genotype (group 1/2)	22/8
HCV RNA (Log copies/mL)	5.6 ± 0.8
Chronic hepatitis/Child-Pugh A cirrhosis/Child-Pugh B cirrhosis/Child-Pugh C cirrhosis	6/20/4/0

Table 1. Characteristics of the H. pylori-Positive Patients (N = 30)

Age (years)

68.8 ± 5.0

Gender (male/female)

16/14

AST (IU/L)

60.5 ± 33.1

ALT (IU/L)

57.8 ± 42.5

γ-GTP (IU/L)

47.0 ± 31.3

ALP (IU/L)

281.5 ± 87.6

Total bilirubin (mg/dL)

0.9 ± 0.3

Albumin (g/dL)

3.8 ± 0.5

Hemoglobin (g/dL)

12.3 ± 1.8

Platelets (× 10³/μL)

98.2 ± 40.9

Prothrombin time (%)

80.9 ± 12.0

HCV genotype (group 1/2)

22/8

HCV RNA (Log copies/mL)

5.6 ± 0.8

Chronic hepatitis/Child-Pugh A cirrhosis/Child-Pugh B cirrhosis/Child-Pugh C cirrhosis

6/20/4/0

**Table 2.** Pre-Treatment Characteristics of Patients With Helicobacter pylori Eradication (N = 19)
Age (years)	68.1 ± 5.3
Gender (male/female)	8/11
AST (IU/L)	54.6 ± 30.8
ALT (IU/L)	50.8 ± 42.6
γ-GTP (IU/L)	41.4 ± 30.3
ALP (IU/L)	280.9 ± 103.4
Total bilirubin (mg/dL)	1.0 ± 0.3
Albumin (g/dL)	3.8 ± 0.5
Hemoglobin (g/dL)	12.1 ± 1.7
Platelets (× 10³/μL)	91.6 ± 30.2
Prothrombin time (%)	80.8 ± 12.8
HCV genotype (group 1/2)	14/5
HCV RNA (Log copies/mL)	5.7 ± 0.8
Chronic hepatitis/Child-Pugh A cirrhosis/Child-Pugh B cirrhosis/Child-Pugh C cirrhosis	4/13/2/0

Table 2. Pre-Treatment Characteristics of Patients With Helicobacter pylori Eradication (N = 19)

Age (years)

68.1 ± 5.3

Gender (male/female)

8/11

AST (IU/L)

54.6 ± 30.8

ALT (IU/L)

50.8 ± 42.6

γ-GTP (IU/L)

41.4 ± 30.3

ALP (IU/L)

280.9 ± 103.4

Total bilirubin (mg/dL)

1.0 ± 0.3

Albumin (g/dL)

3.8 ± 0.5

Hemoglobin (g/dL)

12.1 ± 1.7

Platelets (× 10³/μL)

91.6 ± 30.2

Prothrombin time (%)

80.8 ± 12.8

HCV genotype (group 1/2)

14/5

HCV RNA (Log copies/mL)

5.7 ± 0.8

Chronic hepatitis/Child-Pugh A cirrhosis/Child-Pugh B cirrhosis/Child-Pugh C cirrhosis

4/13/2/0

**Table 3.** Changes in the Platelet Count Between Pre- and Post-Helicobacter pylori Eradication
Factors	Classification	Platelet count	P-value
Age	≥ 70 years (N = 8)	10.3 ± 2.9	11.1 ± 4.4	0.273
< 70 years (N = 11)	8.2 ± 2.7	9.2 ± 2.6	0.116
Sex	Male (N = 10)	9.6 ± 3.2	11.3 ± 4.4	0.125
Female (N = 9)	8.9 ± 2.8	9.3 ± 2.9	0.253
Platelet count before treatment	≥ 800 × 10³/µL (N = 10)	8.2 ± 2.7	9.2 ± 2.6	0.116
< 800 × 10³/µL (N = 9)	7.2 ± 1.2	8.0 ± 1.8	0.188
Splenomegaly	Present (N = 6)	7.9 ± 2.8	8.5 ± 2.7	0.593
Absent (N = 13)	9.8 ± 2.8	11.0 ± 3.7	0.040
Previous interferon treatment	Present (N = 6)	9.3 ± 2.4	9.5 ± 2.8	0.343
Absent (N = 13)	9.2 ± 3.2	10.4 ± 4.0	0.081
Hepatocellular carcinoma	Present (N = 11)	8.8 ± 3.3	10.0 ± 4.1	0.137
Absent (N = 8)	9.7 ± 2.4	10.3 ± 3.1	0.230

Table 3. Changes in the Platelet Count Between Pre- and Post-Helicobacter pylori Eradication

Factors

Classification

Platelet count

P-value

Pre-eradication

Post-eradication

Age

≥ 70 years (N = 8)

10.3 ± 2.9

11.1 ± 4.4

0.273

< 70 years (N = 11)

8.2 ± 2.7

9.2 ± 2.6

0.116

Sex

Male (N = 10)

9.6 ± 3.2

11.3 ± 4.4

0.125

Female (N = 9)

8.9 ± 2.8

9.3 ± 2.9

0.253

Platelet count before treatment

≥ 800 × 10³/µL (N = 10)

8.2 ± 2.7

9.2 ± 2.6

0.116

< 800 × 10³/µL (N = 9)

7.2 ± 1.2

8.0 ± 1.8

0.188

Splenomegaly

Present (N = 6)

7.9 ± 2.8

8.5 ± 2.7

0.593

Absent (N = 13)

9.8 ± 2.8

11.0 ± 3.7

0.040

Previous interferon treatment

Present (N = 6)

9.3 ± 2.4

9.5 ± 2.8

0.343

Absent (N = 13)

9.2 ± 3.2

10.4 ± 4.0

0.081

Hepatocellular carcinoma

Present (N = 11)

8.8 ± 3.3

10.0 ± 4.1

0.137

Absent (N = 8)

9.7 ± 2.4

10.3 ± 3.1

0.230